Business Context and Reporting Period
This Form 8-K filing by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) reports on the Annual Meeting of Stockholders held on June 21, 2017. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Dr. Derek Chalmers: Elected with 9,723,635 votes for, 1,280,647 votes withheld, and 13,758,180 broker non-votes.
- Mr. Martin Vogelbaum: Elected with 9,171,424 votes for, 1,832,858 votes withheld, and 13,758,180 broker non-votes.
- Both directors were elected to serve until the 2020 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2017.
- Votes For: 24,181,296
- Votes Against: 508,356
- Votes Abstain: 72,810
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the company name is Cara Therapeutics, Inc. (the input metadata incorrectly listed Tvardi Therapeutics, Inc.).
- Confirm the election of Dr. Derek Chalmers and Mr. Martin Vogelbaum to the Board of Directors.
- Note the significant number of broker non-votes (13,758,180) on the director election proposals.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2017 fiscal year.